Haemophilus influenzae: Difference between revisions
(Created page with "==Background== ==Antibiotic Sensitivities<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== {| class="wikitable" | align="center" style="background:#f0f0f0;"|'''Cat...") |
(Add Rifampin AntibioticDose entry) |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*[[Gram negative bacteria|Gram negative]] coccobacillus | |||
*Facultative anaerobe | |||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ||
| Line 149: | Line 151: | ||
==Table Overview== | ==Table Overview== | ||
{{Clinically Relevant Bacteria}} | {{Clinically Relevant Bacteria}} | ||
==Management== | |||
===Antibiotic Dosing=== | |||
*{{AntibioticDose|drug=Rifampin|dose=<1 mo; 10mg/kg PO/IV q24h x4 days; Max: 600 mg/day; 1+ mo; 20 mg/kg PO/IV q24h x4 days; Max: 600 mg/day|context=H. influenza prophylaxis|disease=Haemophilus influenzae|population=Pediatric}} | |||
==See Also== | ==See Also== | ||
Latest revision as of 10:58, 20 March 2026
Background
- Gram negative coccobacillus
- Facultative anaerobe
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
Table Overview
| ||||||||||||||||||||||||||||||||||||||||
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014
Management
Antibiotic Dosing
- Rifampin <1 mo; 10mg/kg PO/IV q24h x4 days; Max: 600 mg/day; 1+ mo; 20 mg/kg PO/IV q24h x4 days; Max: 600 mg/day